MOG-IgG Among Participants in the Pediatric Optic Neuritis Prospective Outcomes Study

John J Chen; Stacy L Pineles; Michael X Repka; Sean J Pittock; Robert J Henderson; Grant T Liu; Pediatric Eye Disease Investigator Group (PEDIG)

doi:10.1001/jamaophthalmol.2021.0349

MOG-IgG Among Participants in the Pediatric Optic Neuritis Prospective Outcomes Study

JAMA Ophthalmol. 2021 May 1;139(5):583-585. doi: 10.1001/jamaophthalmol.2021.0349.

Authors

John J Chen^{1

2

3

4}, Stacy L Pineles⁵, Michael X Repka⁶, Sean J Pittock², Robert J Henderson⁷, Grant T Liu⁸; Pediatric Eye Disease Investigator Group (PEDIG)

Affiliations

¹ Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota.
² Department of Neurology, Mayo Clinic, Rochester, Minnesota.
³ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
⁴ Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota.
⁵ UCLA Stein Eye Institute, University of California, Los Angeles.
⁶ Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.
⁷ Jaeb Center for Health Research, Tampa, Florida.
⁸ Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Abstract

This study examines the association of myelin oligodendrocyte glycoprotein immunoglobulin G–associated disorder with pediatric optic neuritis to guide prognosis and treatment.

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Autoantibodies
Child
Humans
Immunoglobulin G
Myelin-Oligodendrocyte Glycoprotein
Optic Neuritis* / diagnosis
Optic Neuritis* / drug therapy
Prospective Studies

Substances

Autoantibodies
Immunoglobulin G
Myelin-Oligodendrocyte Glycoprotein